Eisbach Bio is a precision oncology company developing allosteric small molecule drugs that selectively target molecular machines driving tumor genome reorganization. The company utilizes its proprietary ALLOS platform to exploit synthetic lethality vulnerabilities in genetically defined cancers. This approach aims to create first-in-class, safe, and effective targeted therapies for difficult-to-treat malignancies.
Funding
$12.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPFounders
Product
Problem
Many cancers rely on specific molecular machines to reorganize their genome, making them vulnerable to targeted therapies. However, traditional approaches to drug discovery often result in toxic side effects and the development of resistance.
Solution
Eisbach Bio develops allosteric small molecule inhibitors that selectively disrupt molecular machines essential for tumor genome reorganization. By targeting chromatin remodeling enzymes and helicases, Eisbach's approach exploits specific genetic vulnerabilities in tumors, particularly those with homologous recombination deficiencies. This enables the development of precision oncology therapies that enhance efficacy while minimizing side effects, offering a new approach to synthetic lethality. The ALLOS platform systematically recapitulates the tight controls that strictly regulate the activity of cancer-driving molecular machines, allowing for the development of targeted allosteric therapies for chromatin reorganization.
Target Audience
The primary target audience includes patients with solid tumors, particularly breast, ovarian, pancreatic, and prostate cancers, who have deficiencies in homologous recombination (HRD-positive) and may benefit from synthetic lethality approaches.
Features
- ALLOS platform for discovering allosteric drugs that disrupt vital molecular controls
- Focus on molecular machines essential to the dynamic reorganization of the cancer genome
- Development of selective drugs targeting nucleosome remodeling enzymes and DNA-dependent nuclear helicases
- Small molecule candidates inhibit the activation of cancer-promoting molecular machines
- Designed to enable powerful combination treatments and suppress resistance mechanisms toward targeted cancer therapies
- First-in-class therapies with fewer side effects compared to traditional approaches